European Journal of Internal Medicine
Volume 19, Issue 2 , Pages 99-103 , March 2008

Multiple endocrine neoplasia type 1

Received 10 March 2007 ,Revised 6 July 2007 ,Accepted 30 August 2007.

References 

  1. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658–5671
  2. Trump D, Farren B, Wooding C, et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM. 1996;89:653–669
  3. Heath H, Hodgson SF, Kennedy MA. Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med. 1980;302:189–193
  4. Geerdink EA, Van der Luijt RB, Lips CJ. Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening?. Eur J Endocrinol. 2003;149:577–582
  5. Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger–Ellison syndrome. N Engl J Med. 1999;341:635–644
  6. Levy-Bohbot N, Merle C, Goudet P, et al. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol. 2004;28:1075–1081
  7. Corbetta S, Pizzocaro A, Peracchi M, Beck-Peccoz P, Faglia G, Spada A. Multiple endocrine neoplasia type 1 in patients with recognized pituitary tumours of different types. Clin Endocrinol (Oxf). 1997;47:507–512
  8. Yoshimoto K, Saito S. Clinical characteristics in multiple endocrine neoplasia type 1 in Japan: a review of 106 patients. Nippon Naibunpi Gakkai Zasshi. 1991;67:764–774
  9. Godwin JD. Carcinoid tumors. An analysis of 2,837 cases. Cancer. 1975;36:560–569
  10. Duh QY, Hybarger CP, Geist R, et al. Carcinoids associated with multiple endocrine neoplasia syndromes. Am J Surg. 1987;154:142–148
  11. Skogseid B, Larsson C, Lindgren PG, et al. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 1992;75:76–81
  12. Berdjis CC. Pluriglandular syndrome. II. Multiple endocrine adenomas in man. A report of five cases and a review of literature. Ophthalmologica. 1962;15:288–311
  13. Brandi ML, Marx SJ, Aurbach GD, Fitzpatrick LA. Familial multiple endocrine neoplasia type I: a new look at pathophysiology. Endocr Rev. 1987;8:391–405
  14. Vasen HF, Griffioen G, Lips CJ, Struyvenberg A, van Slooten EA. Screening of families predisposed to cancer development in The Netherlands. Anticancer Res. 1990;10:555–563
  15. Uchino S, Noguchi S, Sato M, et al. Screening of the Men1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors. Cancer Res. 2000;60:5553–5557
  16. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276:404–407
  17. Guru SC, Goldsmith PK, Burns AL, et al. Menin, the product of the MEN-1 gene, is a nuclear protein. Proc Natl Acad Sci USA. 1998;95:1630–1634
  18. La P, Silva AC, Hou Z, Wang H, Schnepp RW, Yan N, et al. Direct binding of DNA by tumor suppressor menin. J Biol Chem. 2004;279:49045–49054
  19. Suphapeetiporn K, Greally JM, Walpita D, Ashley T, Bale AE. MEN1 tumor-suppressor protein localizes to telomeres during meiosis. Genes Chromosomes Cancer. 2002;35:81–85
  20. Agarwal SK, Guru SC, Heppner C, et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell. 1999;96:143–152
  21. Poisson A, Zablewska B, Gaudray P. Menin interacting proteins as clues toward the understanding of multiple endocrine neoplasia type 1. Cancer Lett. 2003;189:1–10
  22. Sukhodolets KE, Hickman AB, Agarwal SK, et al. The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN-1 tumor suppressor gene. Mol Cell Biol. 2003;23:493–509
  23. Sakurai A, Katai M, Itakura Y, Ikeo Y, Hashizume K. Premature centromere division in patients with multiple endocrine neoplasia type 1. Cancer Genet Cytogenet. 1999;109:138–140
  24. Schnepp RW, Chen YX, Wang H, et al. Mutation of tumor suppressor gene MEN-1 acutely enhances proliferation of pancreatic islet cells. Cancer Res. 2006;66:5707–5715
  25. Schnepp RW, Mao H, Sykes SM, et al. Menin induces apoptosis in murine embryonic fibroblasts. J Biol Chem. 2004;279:10685–10691
  26. Kim YS, Burns AL, Goldsmith PK, et al. Stable overexpression of MEN-1 suppresses tumorigenicity of RAS. Oncogene. 1999;18:5936–5942
  27. Stalberg P, Grimfjard P, Santesson M, et al. Transfection of the multiple endocrine neoplasia type 1 gene to a human endocrine pancreatic tumor cell line inhibits cell growth and affects expression of JunD, delta-like protein 1/preadipocyte factor-1, proliferating cell nuclear antigen, and QM/Jif-1. J Clin Endocrinol Metab. 2004;89:2326–2337
  28. Marx SJ, Agarwal SK, Kester MB, et al. Germline and somatic mutation of the gene for multiple endocrine neoplasia type 1 (MEN-1). J Intern Med. 1998;243:447–453
  29. Marx SJ, Agarwal SK, Kester MB, et al. Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog Horm Res. 1999;54:397–439
  30. Crabtree JS, Scacheri PC, Ward JM, et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci USA. 2001;98:1118–1123
  31. Crabtree JS, Scacheri PC, Ward JM, et al. Of mice and MEN-1: Insulinomas in a conditional mouse knockout. Mol Cell Biol. 2003;23:6075–6085
  32. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68:820–823
  33. Tahara H, Smith AP, Gaz RD, Cryns VL, Arnold A. Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Cancer Res. 1996;56:599–605
  34. Farnebo F, Teh BT, Dotzenrath C, et al. Differential loss of heterozygosity in familial, sporadic and uremic hyperparathryoidism. Hum Genet. 1997;99:342–349
  35. Teh BT, Hayward NK, Wilkinson S, Woods GM, Cameron D, Shepherd JJ. Clonal loss of INT-2 alleles in sporadic and familial pancreatic endocrine tumors. Br J Cancer. 1990;62:253–254
  36. Debelenko LV, Zhuang Z, Emmert-Buck MR, et al. Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res. 1997;57:2238–2243
  37. Bates AS, Farrell WE, Bicknell EJ, et al. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab. 1997;82:818–824
  38. Dong Q, Debelenko LV, Chandrasekharappa SC, et al. Loss of heterozygosity at 11q13: analysis of pituitary tumors, lung carcinoids, lipomas, and other uncommon tumors with familial multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 1997;82:1416–1420
  39. Jakobovitz O, Nass D, DeMarco L, et al. Carcinoid tumors frequently display genetic abnormalities involving chromosome 11. J Clin Endocrinol Metab. 1996;81:3164–3167
  40. Debelenko LV, Emmert-Buck MR, Zhuang Z, et al. The multiple endocrine neoplasia type 1 gene locus is involved in the pathogenesis of type 2 gastric carcinoids. Gastroenterology. 1997;113:773–781
  41. Pack S, Turner ML, Zhuang Z, et al. Cutaneous tumors in patients with multiple endocrine neoplasia type 1 show allelic deletion of the MEN-1 gene. J Invest Dermatol. 1998;110:438–440
  42. Heppner C, Kester MB, Agarwal SK, et al. Somatic mutation of the MEN-1 gene in parathyroid tumors. Nat Genet. 1997;16:375–378
  43. Zhuang Z, Vortmeyer AO, Pack S, et al. Somatic mutations of the MEN-1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res. 1997;57:4682–4686
  44. Goebel SU, Heppner C, Burns AL, et al. Genotype/phenotype correlation of multiple endocrine neoplasia type 1 gene mutations in sporadic gastrinomas. J Clin Endocrinol Metab. 2000;85:116–123
  45. Chudek J, Piecha G, Nieszporek T, Marini F, Brandi ML, Wiecek A. Novel 1113delC menin gene mutation in a Polish family with multiple endocrine neoplasia type 1 syndrome. Eur J Intern Med. 2006;17:447–449
  46. Benson L, Ljunghall S, Akerstrom G, Oberg K. Hyperparathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1. Am J Med. 1987;82:731–737
  47. Hagstrom E, Lundgren E, Rastad J, Hellman P. Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur J Endocrinol. 2006;155:33–39
  48. Metz DC, Jensen RT, Bale A, et al. Multiple endocrine neoplasia type 1: Clinical features and management. In:  Bilezikian JP,  Levine MA,  Marcus R editor. The Parathyroids. New York: Raven; 1994;p. 591–646
  49. Frucht H, Howard JM, Slaff JI, Wank SA, McCarthy DM, Maton PN, et al. Secretin and calcium provocative tests in the Zollinger–Ellison syndrome. A prospective study. Ann Intern Med. 1989;111:713–722
  50. Karam JH. Hypoglycemic disorders. In:  Greenspan FS,  Gardner DG editor. Basic and Clinical Endocrinology. Columbus: McGraw Hill; 2001;p. 753–770
  51. Granberg D, Stridsberg M, Seensalu R, et al. Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 1999;84:2712–2717
  52. Tortosa F, Chico A, Rodriguez-Espinosa J, Ruscalleda J, de Leiva A. MEN1 Study Group. Prevalence of MEN 1 in patients with prolactinoma. Clin Endocrinol (Oxf). 1999;50:272
  53. Marx SJ. Multiple endocrine neoplasia type 1. In:  Bilezikian JP,  Marcus R,  Levine MA editor. The Parathyroids. Academic Press; 2001;p. 535–584
  54. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90:135–141
  55. Wada M, Furuya Y, Sakiyama J, et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest. 1997;100:2977–2983
  56. Triponez F, Goudet P, Dosseh D, et al. Is surgery beneficial for MEN-1 patients with small (=2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg. 2006;30:654–662
  57. Kouvaraki MA, Shapiro SE, Cote GJ, et al. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg. 2006;30:643–653
  58. Metz DC, Pisegna JR, Fishbeyn VA, Benya RV, Jensen RT. Control of gastric acid hypersecretion in the management of patients with Zollinger–Ellison syndrome. World J Surg. 1993;17:468–480
  59. Norton JA. Intraoperative methods to stage and localize pancreatic and duodenal tumors. Ann Oncol. 1999;10(Suppl 4):182–184
  60. Boukhman MP, Karam JM, Shaver J, Siperstein AE, DeLorimier AA, Clark OH. Localization of insulinomas. Arch Surg. 1999;134:818–823
  61. Pereira PL, Roche AJ, Maier PE, Huppert GW, Dammann F, Farnsworth CT, et al. Insulinoma and islet cell hyperplasia: value of the calcium intraarterial stimulation test when findings of other preoperative studies are negative. Radiology. 1998;206:703–709
  62. O'Brien T, O'Riordan DS, Gharib H, Scheithauer BW, Ebersold MJ, van Heerden JA. Results of treatment of pituitary disease in multiple endocrine neoplasia, type I. Neurosurgery. 1996;39:273–279
  63. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 1992;13:220–240

PII: S0953-6205(07)00262-2

doi: 10.1016/j.ejim.2007.08.004

European Journal of Internal Medicine
Volume 19, Issue 2 , Pages 99-103 , March 2008

Article Tools